Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00871377 · ClinicalTrials.gov registry record · Phase 2
Double Blind, Crossover Study of Fish Oil [EPA and DHA] for Intractable Partial Seizures
A Phase 2 study of Epilepsy, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT00871377 is a Phase 2 study of Epilepsy that has completed, run by National Center for Complementary and Integrative Health (NCCIH). The registered enrollment target is 24 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00871377, a Phase 2 study of Epilepsy, has completed, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if Omega-3 fatty acids reduce seizures and modify cardiac risk factors in people with epilepsy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG High Dose Fish Oil
- DRUG Low Dose Fish Oil
Study Locations (1)
California
- UCLA General Clinical Research Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2008-05 |
| Est. Completion | 2011-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00871377
The ClinicalTrials.gov registry entry for NCT00871377 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (97% lower). The listed sponsor is National Center for Complementary and Integrative Health (NCCIH), which has 203 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00871377 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00871377 about?
NCT00871377 is a clinical study titled "Double Blind, Crossover Study of Fish Oil [EPA and DHA] for Intractable Partial Seizures". The purpose of this study is to determine if Omega-3 fatty acids reduce seizures and modify cardiac risk factors in people with epilepsy.
What is the current status of trial NCT00871377?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2008-05. Estimated completion is 2011-08.
What conditions does trial NCT00871377 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT00871377?
The interventions under investigation include: Placebo (DRUG), High Dose Fish Oil (DRUG), Low Dose Fish Oil (DRUG).
Who is sponsoring clinical trial NCT00871377?
This trial is sponsored by National Center for Complementary and Integrative Health (NCCIH), which has 203 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00871377 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
RECRUITING · Phase 2
-
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
RECRUITING · Phase 2
-
RNS System LGS Feasibility Study
ACTIVE NOT RECRUITING · Phase 2
-
Study of an External Responsive Neurostimulator System on Epileptiform Activity
COMPLETED · Phase 2
-
Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI
COMPLETED · Phase 2
-
Hormone Replacement in Menopausal Women With Epilepsy
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.